非小细胞肺癌中EGFR酪氨酸激酶抑制剂获得性耐药的机制
Mechanisms of Acquired Resisitance to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
摘要
表皮生长因子受体（epidermal growth factor receptor,EGFR）酪氨酸激酶抑制剂——厄洛替尼，可有效治疗含有EGFR突变的非小细胞肺癌（non—small cell lung cancer,NSCLC），然而，分子靶向药物疗效维持时间较短，几乎所有起初治疗有效的患者最终均会复发，提示对此类药物产生耐药。因此，阐明其耐药的具体机制并研发第二代酪氨酸激酶抑制剂以有效治疗这些肿瘤就显得尤为重要。近年的研究已证实存在两种不同的EGFR酪氨酸激酶抑制剂的耐药机制，
出处
《中国肺癌杂志》
CAS
2009年第12期1346-1351,共6页
Chinese Journal of Lung Cancer
参考文献50
-
1Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290(16): 2149-2158. 被引量：1
-
2Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non,small- cell lung cancer. J Clin Oncol, 2003, 21 (12): 2237-2246. 被引量：1
-
3Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non -small-cell lung cancer.J Clin Oncol, 2004, 22(16): 3238-3247. 被引量：1
-
4Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebocontrolled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract 7022]. Proc Am Soc Clin Oncol, 2004, 22(145): 7022. 被引量：1
-
5Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537. 被引量：1
-
6Paez JG, Janne PA, Lee JC, et al. EGFRmutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500. 被引量：1
-
7LynchTJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N EnglJ Med, 2004, 350(21 ): 2129-2139. 被引量：1
-
8Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311. 被引量：1
-
9Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst, 2005, 97(5): 339-346. 被引量：1
-
10Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol, 2005, 23(14): 3227-3234. 被引量：1
-
1高建峰.奈达铂联合吉西他滨治疗晚期非小细胞肺癌的疗效及不良反应[J].世界最新医学信息文摘,2014,14(28):223-223.
-
2杜艳萍,江兴堂,尹小文,袁亚婷.表皮生长因子受体基因突变在晚期非小细胞肺癌维持治疗中的作用[J].中国新药杂志,2010,19(17):1580-1584. 被引量：2
-
3李莹,田驰,王磊,谢蒙蒙,程泽能.小分子表皮生长因子受体酪氨酸激酶抑制剂的研究进展[J].肿瘤药学,2016,6(2):81-88. 被引量：19
-
4张涛.多西紫杉醇联合卡铂治疗晚期非小细胞肺癌31例[J].中国实用医刊,2008,35(12):88-89. 被引量：1
-
5周严,韩宝惠.靶向治疗时代下的非小细胞肺癌化疗现状与进展[J].上海医药,2015,36(15):9-13. 被引量：7
-
6杨衿记.西妥昔单抗联合化疗治疗晚期非小细胞肺癌(FLEX):一项开放性随机对照Ⅲ期临床试验[J].循证医学,2009,9(3):134-134.
-
7朱亚宁,张鹏,张丹,尤海生,李东辉,何恒,李黎.评估吉非替尼交替化疗对比化疗治疗Ⅳ期非小细胞肺癌的疗效及安全性[J].中国医院药学杂志,2016,36(6):480-484. 被引量：12
-
8徐波,欧阳贵平,柯杨.抗肿瘤药物EGFR抑制剂的研究进展[J].精细化工中间体,2007,37(3):10-14.
-
9谭涵,曾凡新,姜立花,董志,傅洁民.阿法替尼与PF-04691502单用及联合对H1975细胞体外抗肿瘤作用研究[J].第三军医大学学报,2014,36(12):1291-1294. 被引量：1
-
10邓秋媚.多西他赛联合顺铂治疗非小细胞肺癌的观察及护理[J].护理实践与研究,2009,6(14):49-50. 被引量：2
